검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed (Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed) GlaxoSmithKline·HIV Infections ORR 98.1% |
|---|---|
Overview Program | Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed |
Overview Company | GlaxoSmithKline |
Overview Modality | ADC |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeting the Toll-like receptor |
PK/PD Species | Rat, Likewise |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | Likewise, no treatment-related embryo-fetal developmental toxicity or teratogenic effects were observed. |
Toxicology Species | Rat, Likewise |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Preclinical study on an adsorbed acellular diphtheria- tetanus-pertussis (reduced-dose) combined vaccine: evaluation of reproductive safety and immunogenicity.. The diphtheria, tetanus, and acellular pertussis combined vaccine (DTaP) is a trivalent formulation containing acellular pertussis antigens, diphtheria toxoid, and tetanus toxoid, and provides simultaneous protection against pertussis, dip… |
Clinical Primary efficacy | ORR 98.1% |
Clinical ORR | 98.1% |
Clinical Result source | ClinicalTrials.gov NCT00289913 |
Clinical Data Tier / Score | A · 49 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed (Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed) GlaxoSmithKline·HIV Infections ORR 98.1% |
|---|---|
Overview Program | Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed |
Overview Company | GlaxoSmithKline |
Overview Modality | ADC |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeting the Toll-like receptor |
PK/PD Species | Rat, Likewise |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | Likewise, no treatment-related embryo-fetal developmental toxicity or teratogenic effects were observed. |
Toxicology Species | Rat, Likewise |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Preclinical study on an adsorbed acellular diphtheria- tetanus-pertussis (reduced-dose) combined vaccine: evaluation of reproductive safety and immunogenicity.. The diphtheria, tetanus, and acellular pertussis combined vaccine (DTaP) is a trivalent formulation containing acellular pertussis antigens, diphtheria toxoid, and tetanus toxoid, and provides simultaneous protection against pertussis, dip… |
Clinical Primary efficacy | ORR 98.1% |
Clinical ORR | 98.1% |
Clinical Result source | ClinicalTrials.gov NCT00289913 |
Clinical Data Tier / Score | A · 49 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교